Volume 5.03 | Jan 28

Pulmonary Cell News 5.03 January 28, 2016
Pulmonary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   PULCN on Twitter
 
TOP STORY
Simple In Vitro Models Can Predict Pulmonary Toxicity of Silver Nanoparticles
Investigators determined the correlation between in vitro and in vivo data by comparing the dose metrics of silver nanoparticles in an in vitro lung model of increasing complexity to a previously published in vivo inhalation study. [Nanotoxicology] Abstract
Watch Now: Webinar on Gastrointestinal Organoids by Dr. Meritxell Huch
 
PUBLICATIONS (Ranked by impact factor of the journal)
The Endogenous Cannabinoid Anandamide Increases Human Airway Epithelial Cell Permeability through an Arachidonic Acid Metabolite
Researchers studied the effects of endocannabinoids on bronchial epithelial cell permeability and investigated the mechanisms involved. Calu-3 human bronchial epithelial cells were cultured at air-liquid interface to allow development of tight junctions. [Pharmacol Res] Abstract

Electrolyte Transport Properties in Distal Small Airways from Cystic Fibrosis Pigs with Implications for Host Defense
The authors adapted a novel protocol to isolate small airway epithelial cells from cystic fibrosis (CF) and non-CF pigs and established an organotypic culture model. Compared to non-CF large airways, non-CF small airway epithelia cultures had higher Cl and bicarbonate short-circuit currents and higher airway surface liquid pH under 5 percent CO2 conditions. [Am J Physiol Lung Cell Mol Physiol] Abstract

Interferon Regulatory Factor 7 Regulates Airway Epithelial Cell Responses to Human Rhinovirus Infection
At present, the molecular mechanisms that underpin human rhinoviruses responses in airway epithelial cells are incompletely understood. Scientists employed microarray profiling, upstream regulator analysis, and siRNA mediated gene silencing to further the understanding of the role of interferon regulatory factor 7 in this response. [BMC Genomics] Full Article

Impaired Antiviral Stress Granule and IFN-β Enhanceosome Formation Enhances Susceptibility to Influenza Infection in COPD Epithelium
Researchers showed that primary bronchial epithelial cells from subjects with chronic obstructive pulmonary disease (COPD) have impaired induction of type I interferon (IFN) and lead to heightened viral replication following influenza viral infection. [Am J Respir Cell Mol Biol] Abstract

LUNG CANCER

Ninjurin1 Suppresses Metastatic Property of Lung Cancer Cells through Inhibition of Interleukin-6 Signaling Pathway
Researchers showed that inhibition of nerve injury-induced protein 1 (Ninjurin1, Ninj1) promotes lung cancer metastasis through IL-6/STAT3 signaling. Ninj1 levels were relatively low in highly motile lung cancer cells. While inhibition of Ninj1 enhanced cell migration in lung cancer cells, overexpression of Ninj1 significantly suppressed it. [Int J Cancer] Abstract

Interleukin-33 Enhances Programmed Oncosis of ST2L-Positive Low-Metastatic Cells in the Tumor Microenvironment of Lung Cancer
Researchers showed that ST2 was significantly downregulated in human lung cancer tissues and cells compared with normal lung tissues and cells. Interleukin-33 expression was also inversely correlated with the stages of human lung cancers. [Cell Death Dis] Full Article

ADAM23 Is Down-Regulated in Side Population and Suppresses Lung Metastasis of Lung Carcinoma Cells
To examine the members of the ADAM, ADAMTS and MMP gene families related to phenotypes of side population (SP) and main population (MP), the authors screened the expression of all the members in the propagated SP and MP of A549 lung adenocarcinoma cells, and found that the relative expression ratio of ADAM23 in MP to SP is most highly increased, but none of them is increased in SP. [Cancer Sci] Abstract

Aspirin Inhibits Epithelial-to-Mesenchymal Transition and Migration of Oncogenic K-Ras-Expressing Non-Small Cell Lung Carcinoma Cells by Down-Regulating E-Cadherin Repressor Slug
Researchers aimed to discern the molecular mechanisms that regulate Slug/E-cadherin axis in oncogenic K-ras-expressing non-small cell lung carcinoma cells, and the effect of aspirin in modulating the same. [BMC Cancer] Full Article

Learn More: Model the Human Airway at the Air-Liquid Interface
 
REVIEWS
Lung Cancer Stem Cells: The Root of Resistance
The identification of lung cancer stem cells (CSCs) and their role in tumor biology and treatment resistance may lead to innovative targeted therapies that may ultimately improve clinical outcomes in lung cancer patients. This review focuses on lung CSC markers, their role in resistance and their relevance as targets for future therapies. [Cancer Lett] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.
 
INDUSTRY NEWS
Boehringer Ingelheim’s Giotrif®/Gilotrif® (Afatinib) Demonstrated Superiority to Iressa® (Gefitinib) in Reducing the Risk of Disease Progression and Treatment Failure in First-Line Treatment of Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer
Boehringer Ingelheim announced the results of the LUX-Lung 7 trial. Superiority in progression-free survival and time to treatment failure was demonstrated with second-generation EGFR-directed therapy afatinib, versus first-generation gefitinib in the first-line treatment of patients with advanced non-small cell lung cancer with common EGFR mutations. [Boehringer Ingelheim GmbH] Press Release

Health Canada Approves PrORKAMBI® (Lumacaftor/Ivacaftor) – The First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation
Vertex Pharmaceuticals Incorporated announced that Health Canada has approved PrORKAMBI®, the first medicine to treat the underlying cause of cystic fibrosis in people ages 12 and older with two copies of the F508del mutation. [Vertex Pharmaceuticals Incorporated] Press Release

Lipman Gift Aims at Development of Breakthrough Treatments for Cystic Fibrosis through Sorscher Recruitment
A new philanthropic gift to Emory University will support the advancement of cystic fibrosis research with the aim of developing effective new drug therapies and a cure for the disease. The gift from Eva and Charles Lipman will contribute substantially to the laboratory of Eric J. Sorscher, MD. [Emory University] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells?
Request your free wallchart.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Respiratory Health and Smoking Science Summit
May 24-26, 2016
London, United Kingdom

Visit our events page to see a complete list of events in the pulmonary cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Fellow – Lung Cancer Research (German Cancer Research Center)

Project Scientist – Pulmonary Fibrosis (Cedars Sinai Medical Center)

PhD and MD/PhD Positions – Translational Pulmonary Medicine (Helmholtz Association)

Postdoctoral Fellow – Bioinformatics RNA Biology & Cancer (German Cancer Research Center)

Postdoctoral Fellow/Research Associate – Cancer Therapy (Memorial Sloan Kettering Cancer Center)

Director Clinical Research – Medical Oncology (Fred Hutchinson Cancer Research Center)

Postdoctoral Researcher – Immunology (Research Centre for Respiratory Diseases)

Postdoctoral Research Fellow – Epigenetics/Systems Biology (National Heart, Lung, and Blood Institute)

Professor – Precision Cancer Medicine (German Cancer Research Center)

PhD Positions – Heart and Lung Research (Max Planck Institute for Heart and Lung Research)

Postdoctoral Positions – Lung Cancer Research (University of Texas)

PhD Studentships – Cancer and Allergy (University of Salzburg)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Pulmonary Cell News: Archives | Events | Contact Us